Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Interested parties can access a live webcast and analysts can join the Q&A via designated links; a recording will be posted to the company investor relations website shortly after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: AVIR down 1.03% in momentum scan, while CADL, LYEL, NMRA, and TNXP had both positive and negative moves, suggesting stock-specific factors for IVVD.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Earnings call scheduling | Neutral | -13.0% | Announced Nov 6, 2025 Q3 2025 results and corporate update call. |
| May 08 | Earnings call scheduling | Neutral | +0.8% | Set May 15, 2025 call for Q1 2025 results and updates. |
| Nov 06 | Earnings call scheduling | Neutral | +12.6% | Planned Nov 14, 2024 call on Q3 2024 results and business updates. |
| Aug 12 | Earnings call scheduling | Neutral | +9.8% | Announced Aug 14, 2024 Q2 2024 results and highlights call. |
| May 02 | Earnings call scheduling | Neutral | +2.1% | Outlined May 9, 2024 call for Q1 2024 results and highlights. |
Scheduling earnings/conference calls previously led to mixed single-day moves, with an average change of about 2.47% across five prior events.
Over the last year, Invivyd has regularly announced conference calls to discuss quarterly results and corporate updates, tagged as conferences,earnings. These events on May 2, 2024, Aug 12, 2024, Nov 6, 2024, May 8, 2025, and Nov 3, 2025 produced varied price reactions from modest declines to double‑digit gains. The current announcement of a March 5, 2026 call continues this communication pattern ahead of detailed fourth quarter and full‑year 2025 results.
Historical Comparison
Past earnings-call scheduling headlines for IVVD showed an average one-day move of 2.47%, with reactions ranging from mild declines to notable gains.
Regulatory & Risk Context
Invivyd has an active Form S-3 shelf filed on 2025-10-02. The prospectus reports pro forma net tangible book value of $169.1 million (or $0.58 per share) as of June 30, 2025, and references pre-funded warrants for 21,342,442 shares and two related 424B5 offerings dated November 17–18, 2025.
Market Pulse Summary
This announcement schedules Invivyd’s March 5, 2026 call to review fourth quarter and full-year 2025 results, continuing a pattern of regular conferences,earnings updates. Investors already had preliminary Q4 data, including $17.2M PEMGARDA revenue and expected cash of $226.7M, plus visibility into ongoing VYD2311 trials. The existing Form S-3 shelf with reported net tangible book value of $169.1M and recent insider Rule 10b5‑1 sell-to-cover filings provide additional context to monitor as full financial details are released.
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.
Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company’s investor relations website shortly after the event.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
When will Invivyd (IVVD) hold its Q4 and full-year 2025 earnings call?
How can investors join Invivyd's (IVVD) March 5, 2026 webcast?
Can analysts participate in Invivyd's (IVVD) March 5, 2026 Q&A session?
Will Invivyd (IVVD) provide a recording of the March 5, 2026 earnings webcast?
What topics will Invivyd (IVVD) cover during the March 5, 2026 call?
What time should participants join Invivyd's (IVVD) March 5, 2026 call to avoid technical delays?
